Francesco Massari, Medical Oncologist focused on Genitourinary Cancer at The University Hospital of Bologna IRCCS, shared a post on X:
“Fantastic results by Talapro-2 trial about the combination talazoparib and enzalutamide in 1st line mCRPC.
But.. are we sure that the Parpi are for all patients or just selected ones?”
Quoting Tom Powles‘s post:
“TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC.
It has significant OS in ITT HR=0.796. It’s current used in HRR deficient.
Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve.”\
